TandemAI Merges with Perpetual Medicines to Expand Peptide and AI Drug Discovery Capabilities
July 10, 2025
TandemAI and Perpetual Medicines have merged, with the combined company operating under the TandemAI name. Perpetual Medicines will operate as a separate entity within TandemAI to extend the firm's capabilities into computational peptide design and integrated synthesis, while leadership from both companies will continue in senior roles; financial terms were not disclosed.
- Buyers
- TandemAI
- Targets
- Perpetual Medicines
- Industry
- Biotechnology
- Location
- Shanghai, China
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader
July 8, 2024
Pharmaceuticals
MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.
-
SAI MedPartners Acquires IDEA Pharma
November 14, 2024
Healthcare Services
SAI MedPartners, a global life-sciences consultancy backed by Northlane Capital Partners, has acquired London-headquartered IDEA Pharma to strengthen its pharmaceutical path-to-market, clinical development, and commercialization capabilities. The acquisition is an add-on to SAI's platform, expanding its strategic services offering to biopharma and medical device clients.
-
Tandem Diabetes Care Acquires Capillary Biomedical
July 21, 2022
Medical Devices
Tandem Diabetes Care, Inc. has acquired Capillary Biomedical, a developer of extended-wear insulin infusion set technology. The acquisition (terms not disclosed) brings Capillary's infusion-set R&D into Tandem's product portfolio to expand infusion set options and advance extended-wear solutions for insulin pump users.
-
AbbVie Completes Acquisition of Nimble Therapeutics
January 23, 2025
Biotechnology
AbbVie has completed its acquisition of Nimble Therapeutics, adding Nimble's investigational oral peptide IL23R inhibitor for psoriasis and a peptide synthesis, screening and optimization platform to AbbVie's immunology pipeline. The deal is intended to strengthen AbbVie's R&D capabilities and accelerate discovery and optimization of oral peptide therapeutics.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
Invaio Sciences Acquires Peptyde Bio
December 7, 2023
Biotechnology
Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.